Evaluation of the Safety and Clinical Efficacy of NRICM102 in Patients With Chronic Lower Respiratory Tract Diseases

NCT ID: NCT06690203

Last Updated: 2024-11-15

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Clinical Phase: NA
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-09-30
• Study Completion Date: 2025-12-31

Brief Summary

This study is to assess safety and efficacy of NRICM102 decoction in participants with CLRD. This study will be conducted in 70 participants. The study consists of 3 periods: a 4-week screening period, a treatment period for at least 12 weeks up to 24 weeks.

Detailed Description

• Investigational product(s)： NRICM102 Decoction
• Development Phase: A real-world Prospective study
• Study Design：

1. Experimental Group: Standard of care combined NRICM102 for 12weeks

2. Blinding：Open

3. Randomization: No

4. Parallel design : Not applicable

5. Treatment Period：12 to 24 weeks by groups

6. Study Period: From 01/07/2024 to 31/12/2025

7. Dose adjustment： Not applicable

8. Study location： Single

• Study Procedures： This study is to assess safety and efficacy of NRICM102 decoction in participants with CLRD. This study will be conducted in 70 participants. The study consists of 3 periods: a 4-week screening period, a treatment period for at least 12 weeks up to 24 weeks. In principle, the two groups are divided into 1:1. The study group period is divided into a continuous treatment group and a discontinued treatment group. The purpose is to evaluate the drug safety of continuous treatment for 24 weeks and the similarities and differences in the physiological assessment of the subjects between the two groups, so as to serve as a reference for the design of a combined treatment program of traditional Chinese and Western medicine for chronic respiratory diseases. Since subjects may terminate early during the taking period, we also designed an evaluation time point, and also conducted an evaluation at the early end of time (EOS).
• Statistical Methods：

1. Main study Hypothesis：Not applicable

2. Estimated Sample Size：This study will be conducted in 70 participants. 50 subjects can be evaluated in the trial.

3. Efficacy assessment group：Intent-to-treat (ITT)

4. Interim analysis：No

5. Statistical methods： All participants who have been randomized to study intervention and who have received at least one dose of study intervention will be included in the Efficacy Analysis Set. The Safety Analysis Set is defined as all participants who have been randomized to study intervention.

All results will be presented by treatment with descriptive statistics appropriate to the nature of the variables. Demographic and baseline characteristics will be presented as follows; for continuous variables, the number of non-missing observations, mean, standard deviation (SD), standard error (SE) of the mean, 95% confidence interval (CI) of the mean (except safety data), median, first and third quartiles, minimum and maximum, will be presented; for categorical variables: counts (n) and percentages (%) (where specified) will be presented. These summaries will be provided by time point of assessment as appropriate.

Details on the handling of missing data for the safety or efficacy analyses will be provided.

1. Safety will be assessed by descriptive analysis of vital signs, ECGs, laboratory assessments and AEs reported.

2. Change from baseline in health related QOL questionnaires ACT, ACQ-5, CAT, SGRQ and mMRC, spirometry and walking distance of visit and average over the treatment period will be reported, and subgroup analysis in CLRT will be provided at Weeks 4, 12, 24 and average over the treatment period.

• 6. Handling of Missing Data： The missing data will not be included in the analysis.

Conditions

Chronic Lower Respiratory Diseases

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

A. Combining NRICM102 decoction with standard treatment for 12 weeks

Combining NRICM102 decoction with standard treatment for 12 weeks

Group Type: OTHER

NRICM102

Intervention Type: COMBINATION_PRODUCT

A traditional Chinese medicine formula

B. Combining NRICM102 decoction with standard treatment for 24 weeks

Combining NRICM102 decoction with standard treatment for 24 weeks

Group Type: OTHER

NRICM102

Intervention Type: COMBINATION_PRODUCT

A traditional Chinese medicine formula

Interventions

NRICM102

A traditional Chinese medicine formula

Intervention Type: COMBINATION_PRODUCT

Eligibility Criteria

Inclusion Criteria

• Age ≥18 years of age
• Diagnosed of chronic lower respiratory tract disorder(such as : asthma, COPD, emphysema, chronic bronchitis, bronchiectasis, lung fibrosis) by pulmonologist
• Have symptom of chronic cough, cough with sputum after using of a maintenance respiratory medication and stable disease more than 3 months.
• Willing to be evaluated by a Traditional Chinese Physician whether use of NRICM102 is suitable.
• The patient can use NRICM102 therapy after Traditional Chinese Physician evaluate. Able to understand and sign an informed consent ( or have a legal representative who is able to do so)

Exclusion Criteria

• Females who are breastfeeding or pregnant at screening.
• Life threatening (e.g. intensive care admission and/or use of mechanical ventilation) respiratory failure event in the past 3 months.
• Patients with gastrointestinal malabsorption or condition that might affect the absorption of NRICM102 in the opinion of investigator. (exp: Irritable bowel syndrome, acute gastritis, duodenal ulcer..).
• Acute exacerbation or unstable vital signs on screening stage.
• Patient who have malignancy and receiving chemotherapy/ target therapy at screening.
• Diagnosis of liver cirrhosis or active hepatitis infection.
• Patient having renal dysfunction with Creatinine Clearance Calculator (CCR) < 30mL/min.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Taichung Veterans General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Pin-Kuei Fu, MD, PhD

Director; Integrated Care Center of Interstitial Lung Disease (ICCILD)

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Pin-Kuei Fu

Role: PRINCIPAL_INVESTIGATOR

chairman; Integrated Care Center of Interstitial Lung Disease (ICCILD)

Locations

Taichung Veterans General Hospita

Taichung, No.1650, Taiwan Boulevard Sect. 4, Taiwan

Countries

Taiwan

Other Identifiers

CF24327B

Identifier Type: -

Identifier Source: org_study_id